416 related articles for article (PubMed ID: 18511810)
21. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer.
Lee JW; Ryu JY; Yoon G; Jeon HK; Cho YJ; Choi JJ; Song SY; Do IG; Lee YY; Kim TJ; Choi CH; Kim BG; Bae DS
Int J Cancer; 2015 Jul; 137(1):221-9. PubMed ID: 25429856
[TBL] [Abstract][Full Text] [Related]
22. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
23. Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells.
Edsall LC; Cuvillier O; Twitty S; Spiegel S; Milstien S
J Neurochem; 2001 Mar; 76(5):1573-84. PubMed ID: 11238741
[TBL] [Abstract][Full Text] [Related]
24. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism.
Maceyka M; Sankala H; Hait NC; Le Stunff H; Liu H; Toman R; Collier C; Zhang M; Satin LS; Merrill AH; Milstien S; Spiegel S
J Biol Chem; 2005 Nov; 280(44):37118-29. PubMed ID: 16118219
[TBL] [Abstract][Full Text] [Related]
25. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases.
Gao P; Peterson YK; Smith RA; Smith CD
PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244
[TBL] [Abstract][Full Text] [Related]
26. Short Periods of Hypoxia Upregulate Sphingosine Kinase 1 and Increase Vasodilation of Arteries to Sphingosine 1-Phosphate (S1P) via S1P
Alganga H; Almabrouk TAM; Katwan OJ; Daly CJ; Pyne S; Pyne NJ; Kennedy S
J Pharmacol Exp Ther; 2019 Oct; 371(1):63-74. PubMed ID: 31371480
[TBL] [Abstract][Full Text] [Related]
27. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
[TBL] [Abstract][Full Text] [Related]
28. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.
Schnute ME; McReynolds MD; Kasten T; Yates M; Jerome G; Rains JW; Hall T; Chrencik J; Kraus M; Cronin CN; Saabye M; Highkin MK; Broadus R; Ogawa S; Cukyne K; Zawadzke LE; Peterkin V; Iyanar K; Scholten JA; Wendling J; Fujiwara H; Nemirovskiy O; Wittwer AJ; Nagiec MM
Biochem J; 2012 May; 444(1):79-88. PubMed ID: 22397330
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.
Taha TA; Osta W; Kozhaya L; Bielawski J; Johnson KR; Gillanders WE; Dbaibo GS; Hannun YA; Obeid LM
J Biol Chem; 2004 May; 279(19):20546-54. PubMed ID: 14988393
[TBL] [Abstract][Full Text] [Related]
30. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha.
Pettus BJ; Bielawski J; Porcelli AM; Reames DL; Johnson KR; Morrow J; Chalfant CE; Obeid LM; Hannun YA
FASEB J; 2003 Aug; 17(11):1411-21. PubMed ID: 12890694
[TBL] [Abstract][Full Text] [Related]
31. Sphingosine kinase 1 in cancer.
Heffernan-Stroud LA; Obeid LM
Adv Cancer Res; 2013; 117():201-35. PubMed ID: 23290781
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.
Pchejetski D; Böhler T; Stebbing J; Waxman J
Nat Rev Urol; 2011 Sep; 8(10):569-678. PubMed ID: 21912422
[TBL] [Abstract][Full Text] [Related]
33. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
Hart PC; Chiyoda T; Liu X; Weigert M; Curtis M; Chiang CY; Loth R; Lastra R; McGregor SM; Locasale JW; Lengyel E; Romero IL
Mol Cancer Res; 2019 Apr; 17(4):870-881. PubMed ID: 30655321
[TBL] [Abstract][Full Text] [Related]
34. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.
Bonhoure E; Lauret A; Barnes DJ; Martin C; Malavaud B; Kohama T; Melo JV; Cuvillier O
Leukemia; 2008 May; 22(5):971-9. PubMed ID: 18401414
[TBL] [Abstract][Full Text] [Related]
35. Sphingosine kinase 1 as an anticancer therapeutic target.
Gao Y; Gao F; Chen K; Tian ML; Zhao DL
Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
[TBL] [Abstract][Full Text] [Related]
36. Signaling pathways involved in sphingosine kinase activation and sphingosine-1-phosphate release in rat myometrium in late pregnancy: role in the induction of cyclooxygenase 2.
Serrano-Sanchez M; Tanfin Z; Leiber D
Endocrinology; 2008 Sep; 149(9):4669-79. PubMed ID: 18723875
[TBL] [Abstract][Full Text] [Related]
37. [Sphingosine kinase 1 and tumor].
Zhang CX; He HW; Shao RG
Yao Xue Xue Bao; 2013 Jul; 48(7):971-8. PubMed ID: 24133963
[TBL] [Abstract][Full Text] [Related]
38. Different Roles of Sphingosine Kinase 1 and 2 in Pancreatic Cancer Progression.
Yuza K; Nakajima M; Nagahashi M; Tsuchida J; Hirose Y; Miura K; Tajima Y; Abe M; Sakimura K; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():186-194. PubMed ID: 30463717
[TBL] [Abstract][Full Text] [Related]
39. Increased sphingosine 1-phosphate mediates inflammation and fibrosis in tubular injury in diabetic nephropathy.
Yaghobian D; Don AS; Yaghobian S; Chen X; Pollock CA; Saad S
Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):56-66. PubMed ID: 26414003
[TBL] [Abstract][Full Text] [Related]
40. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy.
Zheng X; Li W; Ren L; Liu J; Pang X; Chen X; Kang D; Wang J; Du G
Pharmacol Ther; 2019 Mar; 195():85-99. PubMed ID: 30347210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
